BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

Published:2014-09 Issue:9 Volume:24 Page:1385-1393
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Angell Trevor E.¹²,Lechner Melissa G.²,Jang Julie K.²,Correa Adrian J.²,LoPresti Jonathan S.³,Epstein Alan L.²

Affiliation:

1. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and the Harvard Medical School, Boston, Massachusetts.

2. Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.

3. Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, Los Angeles, California.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2014.0134

Reference55 articles.

1. Cancer statistics, 2013

2. Recent Trends in the Incidence, Geographical Distribution, and Survival From Thyroid Cancer in Wales, 1985–2010

3. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005

4. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002

5. Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940-1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications;Frontiers in Immunology;2024-09-03

2. Immune Profile of BRAF-Mutant Papillary Thyroid Carcinoma and Its Potential Immune Therapy Strategy;Clinical Thyroidology®;2024-09-01

3. Evaluation of CTLA-4 and PD-L1 Expression in Thyroid Carcinoma and Its Prognostic Significance;Cureus;2024-08-16

4. Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies;Journal for ImmunoTherapy of Cancer;2024-07

5. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers;Clinical Cancer Research;2024-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3